Glycosaminoglycans may help postpone peritoneal failure in long-term continuous ambulatory peritoneal dialysis (CAPD)

This article was originally published in Clinica

09 Oct 1995
News

Executive Summary

Administering glycosaminoglycans to patients on long-term continuous ambulatory peritoneal dialysis (CAPD) may help maintain the efficiency of the treatment, say Italian researchers in the Lancet (September 16th). Previous observations had shown that glycosaminoglycans have a protective effect on peritoneal structure and function in diabetic and other experimental rats.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Industries
Medical Device

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT093606

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT093606

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Glycosaminoglycans may help postpone peritoneal failure in long-term continuous ambulatory peritoneal dialysis (CAPD)

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert